NCR201 / Nuwacell Biotech - LARVOL DELTA

Robot-assisted transplantation of hypoimmune iPSC derived dopaminergic progenitor cells for idiopathic Parkinson’s disease (WPC 2026) - P1 | "Conclusions This clinical result demonstrated that in 7 idiopathic PD patients the NCR201 cell replacement therapy achieved functional engraftment, leading to rapid, substantial, and sustained improvements in both motor and non-motor symptoms. As the first hypoimmune iDAPs product entering clinical trial, these findings showed early promise of NCR201 as a transformative treatment for PD."

Late-breaking abstract • CNS Disorders • Movement Disorders • Parkinson's Disease • Transplantation • FOXA2

Robot-assisted Transplantation of hypoimmune iPSC derived dopaminergic progenitor cells for PRKN associated early-onset Parkinson's disease: A case report (WPC 2026) - "The close correlation between clinical improvement and restored dopaminergic neural innervation presents a prove of concept for NCR201 cell replacement therapy in PRKN-PD intervention. These preliminary findings warrants an expanded study involving more inherited PD patients with long-term observation."

Case report • Clinical • Late-breaking abstract • CNS Disorders • Movement Disorders • Parkinson's Disease • Transplantation • FOXA2

China ‘outpacing the US’ in biotech race to find cure for Parkinson’s disease (South China Morning Post) - "According to Nuwacell, its candidate also appears to trigger less immune rejection following transplant, allowing the cells to survive longer after being implanted into the brain...Follow-up data from its longest-tracked patients showed that increased dopamine function in the brain had been maintained for more than 18 months without decline...According to Shi, all six patients recruited for the trial – which started in the middle of last year – showed rapid improvements in motor control, alongside significant and sustained increases in dopamine signalling in the brain...Nuwacell’s co-founder and chief technology officer Zhang, who holds a PhD from Cornell University, said that in the 12 months from April last year, the company had enrolled nearly 40 patients."

P1 data • Trial status • Parkinson's Disease

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd.

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease